← Back to Search

Local Anesthetic

Ultrasound-Guided Nerve Block for Hip Fractures

N/A
Recruiting
Led By Beatrice Hoffmann, MD PhD
Research Sponsored by Beth Israel Deaconess Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 hours after initiation of study proceduure
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial will compare pain control in people with hip fractures who receive ultrasound-guided femoral nerve blocks to those who receive the standard pain management of an injection of opioid medication.

Who is the study for?
This trial is for adults over 18 who come to the emergency department with a confirmed hip fracture and have moderate to severe pain. They must be able to give consent and participate in the study.
What is being tested?
The study compares two methods of pain management for hip fractures: Ultrasound Guided Femoral Nerve Blockade (USFNB) using bupivacaine versus standard opioid medication like morphine given through injection.
What are the potential side effects?
Possible side effects may include discomfort at the injection site, potential nerve damage from incorrect needle placement, allergic reactions to bupivacaine or morphine, and typical opioid-related side effects such as nausea, drowsiness, or constipation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 hours after initiation of study proceduure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 hours after initiation of study proceduure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
pain intensity reduction

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ultra-sound guided femoral nerve blockExperimental Treatment2 Interventions
Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
Group II: standard of care- IV morphineActive Control1 Intervention
Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved

Find a Location

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
855 Previous Clinical Trials
12,930,901 Total Patients Enrolled
Beatrice Hoffmann, MD PhDPrincipal Investigator - Beth Israel Deaconess Medical
Beth Israel Deaconess Hospital-Plymouth
Ruprecht-Karl-University (Medical School)
York Hospital (Residency)
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top